Lynch & Associates Abb Vie Inc. Transaction History

Lynch & Associates

$429 Million
Q1 2024

A detailed history of Lynch & Associates transactions in Abb Vie Inc. stock. As of the latest transaction made, Lynch & Associates holds 71,015 shares of ABBV stock, worth $12.9 Million. This represents 3.01% of its overall portfolio holdings.

Number of Shares

71,015

Previous 75,458 5.89%

Holding current value

$12.9 Million

Previous $11.7 Million 10.59%

% of portfolio

3.01%

Previous 2.86%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 09, 2024	SELL	$159.82 - $182.1 $710,080 - $809,070	-4,443 Reduced 5.89%	71,015 $12.9 Million
Q4 2023 Jan 08, 2024	SELL	$137.6 - $154.97 $194,704 - $219,282	-1,415 Reduced 1.84%	75,458 $11.7 Million
Q3 2023 Oct 24, 2023	BUY	$133.59 - $154.65 $43,683 - $50,570	327 Added 0.43%	76,873 $11.5 Million
Q2 2023 Oct 24, 2023	SELL	$132.51 - $164.9 $166,565 - $207,279	-1,257 Reduced 1.62%	76,546 $10.3 Million
Q2 2023 Jul 13, 2023	SELL	$132.51 - $164.9 $166,565 - $207,279	-1,257 Reduced 1.62%	76,546 $10.3 Million

Q1 2023 Oct 24, 2023	BUY	$144.61 - $166.54 $181,774 - $209,340	1,257 Added 1.64%	77,803 $12.4 Million
Q1 2023 Apr 04, 2023	SELL	$144.61 - $166.54 $279,820 - $322,254	-1,935 Reduced 2.43%	77,803 $12.4 Million
Q4 2022 Oct 24, 2023	BUY	$138.31 - $165.87 $396,258 - $475,217	2,865 Added 3.73%	79,738 $12.9 Million
Q4 2022 Jan 05, 2023	SELL	$138.31 - $165.87 $50,483 - $60,542	-365 Reduced 0.46%	79,738 $12.9 Million
Q3 2022 Oct 03, 2022	SELL	$134.21 - $153.93 $168,836 - $193,643	-1,258 Reduced 1.55%	80,103 $10.8 Million
Q2 2022 Jul 06, 2022	BUY	$137.62 - $174.96 $15,000 - $19,070	109 Added 0.13%	81,361 $12.5 Million
Q1 2022 Apr 08, 2022	SELL	$131.98 - $163.75 $200,345 - $248,572	-1,518 Reduced 1.83%	81,252 $13.2 Million
Q4 2021 Jan 11, 2022	BUY	$107.43 - $135.93 $11,817 - $14,952	110 Added 0.13%	82,770 $11.2 Million
Q3 2021 Oct 12, 2021	BUY	$106.4 - $120.78 $1,596 - $1,811	15 Added 0.02%	82,660 $8.92 Million
Q2 2021 Jul 21, 2021	BUY	$105.21 - $117.21 $6,207 - $6,915	59 Added 0.07%	82,645 $9.31 Million
Q1 2021 Apr 09, 2021	BUY	$102.3 - $112.62 $127,875 - $140,775	1,250 Added 1.54%	82,586 $8.94 Million
Q4 2020 Jan 20, 2021	SELL	$80.49 - $108.67 $38,635 - $52,161	-480 Reduced 0.59%	81,336 $8.72 Million
Q3 2020 Oct 21, 2020	BUY	$85.91 - $100.83 $712,193 - $835,880	8,290 Added 11.27%	81,816 $7.17 Million
Q2 2020 Jul 20, 2020	SELL	$73.37 - $98.18 $81,220 - $108,685	-1,107 Reduced 1.48%	73,526 $7.22 Million
Q1 2020 Apr 28, 2020	SELL	$64.5 - $97.79 $88,752 - $134,559	-1,376 Reduced 1.81%	74,633 $5.69 Million
Q4 2019 Jan 10, 2020	BUY	$72.13 - $90.25 $250,651 - $313,618	3,475 Added 4.79%	76,009 $6.73 Million
Q3 2019 Oct 03, 2019	SELL	$62.98 - $75.72 $77,087 - $92,681	-1,224 Reduced 1.66%	72,534 $5.49 Million
Q2 2019 Jul 19, 2019	SELL	$65.7 - $83.98 $8,738 - $11,169	-133 Reduced 0.18%	73,758 $5.36 Million
Q1 2019 Apr 25, 2019	SELL	$77.14 - $90.79 $71,663 - $84,343	-929 Reduced 1.24%	73,891 $5.96 Million
Q4 2018 Jan 10, 2019	BUY	$77.85 - $96.01 $1.44 Million - $1.78 Million	18,516 Added 32.89%	74,820 $6.9 Million
Q3 2018 Oct 05, 2018	SELL	$88.91 - $98.84 $336,968 - $374,603	-3,790 Reduced 6.31%	56,304 $5.33 Million
Q2 2018 Jul 09, 2018	BUY	$89.78 - $106.23 $93,101 - $110,160	1,037 Added 1.76%	60,094 $5.57 Million
Q1 2018 Apr 06, 2018	SELL	$92.01 - $123.21 $324,059 - $433,945	-3,522 Reduced 5.63%	59,057 $5.59 Million
Q4 2017 Jan 04, 2018	SELL	$89.56 - $98.21 $32,778 - $35,944	-366 Reduced 0.58%	62,579 $6.05 Million
Q3 2017 Oct 18, 2017	BUY	$69.85 - $89.22 $4.4 Million - $5.62 Million	62,945	62,945 $5.59 Million

Others Institutions Holding ABBV

# of Institutions

3,647

Shares Held

1.23B

Call Options Held

15.5M

Put Options Held

11.5M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $322B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lynch & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Lynch & Associates with notifications on news.

Account

Lynch & Associates Abb Vie Inc. Transaction History